TissueGen Wins MedTech Breakthrough Award

07 Jun TissueGen Wins MedTech Breakthrough Award

TissueGen’s ELUTE® Fiber Recognized with Medical Device Engineering Breakthrough Award

DALLAS, TX, June 7, 2017 – TissueGen® Inc., developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering, today announced that it has been selected as the winner of the “Medical Device Engineering Breakthrough” award from MedTech Breakthrough, an independent organization that recognizes the top companies, technologies and products in the global health and medical technology market today.

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories. This year’s program attracted more than 2,000 nominations from over 10 different countries throughout the world.

TissueGen’s patented process for manufacturing patented and commercially available ELUTE® fiber occurs at or below body temperature thereby preserving the biologic activity of incorporated biologics and pharmaceutical compounds. ELUTE fiber technology enables controlled sustained delivery of a broad range of sensitive biologics and pharmaceuticals directly at the topical application or implant site and may potentially orchestrate and improve the healing process.  ELUTE fiber enables tissue engineering and regenerative medicine applications never before possible.

“We are pleased to recognize TissueGen for their outstanding display of engineering innovation in the development of ELUTE fiber,” said James Johnson, managing director, MedTech Breakthrough. “The competition among medical device and solution engineering award nominations was fierce, and TissueGen displayed a compelling and high-impact solution for a broad range of topical and implantable medical devices products. Congratulations to the TissueGen team on their well-deserved industry recognition.”

“ELUTE fiber has the potential to revolutionize a broad range of medical applications and we are honored by MedTech Breakthrough’s recognition of our team’s development of this innovative drug delivery technology” said Christopher Knowles, president and CEO of TissueGen.

Download TissueGen’s free white paper here for additional information on ELUTE fiber.

 

About TissueGen

TissueGen® Inc. is the developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering. TissueGen manufactures biodegradable polymer-based fibers with the broadest drug delivery capabilities available today. ELUTE fiber can directly replace standard fibers used in medical devices currently on the market and may provide significantly improved clinical outcomes by delivering sensitive therapeutic agents directly at the implant or topical application site in controlled, sustained release profiles. ELUTE fiber may enable medical device developers to guide the body’s healing and regenerative processes.

For more information, please visit www.tissuegen.com.

 

About MedTech Breakthrough The MedTech Breakthrough Awards program is devoted to honoring excellence in medical and health related technology companies, products and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough MedTech companies and products in categories including Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Genomics, Medical Data, Healthcare Cybersecurity and more.

For more information visit www.MedTechBreakthrough.com.

# # #

For more information contact:

Jordan Bouclin

SVM Public Relations

401-490-9700

jordan.bouclin@svmpr.com

 

 

 

 

 

 

 

No Comments

Sorry, the comment form is closed at this time.